Hyder Alikhan

Dr. Hyder Alikhan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
HAHyder Alikhan
Hyder Alikhan
BWBrian White
Brian White
JSJohn D. Sterrett
John D. Sterrett
MFMarina Farag
Marina Farag
CLChristopher Lowry
Christopher Lowry
Sangita PhadtareSangita Phadtare
Sangita Phadtare
Recent evidence suggests that Helicobacter pylori can act outside stomach by influencing the gut microbiome. We hypothesize that interactions between H. pylori and the gut microbiome, and the resulting changes in the gut chemicals (bile acids and bacterial signaling molecules involved in quorum sensing, e.g., autoinducer-2/AI-2), influence pathogen survival, antibiotic response, and disease progression. Our gut microbiome, bile acid, and AI-2 analyses showed that H. pylori patients had decreased alpha diversity (p = 0.05), increased AI-2 concentration (p = 0.019), decreased taurine-conjugated bile acids, and increased unconjugated bile acids. A co-occurring module of Prevotella, Holdemanella, and Subdoligranulum, was higher in patients (p = 0.04) and relative abundance of Allisonella was positively associated with levels of unconjugated bile acids, chenodeoxycholic acid, and cholic acid (p = 0.05 and 0.02, respectively). Our study is the first to characterize the gut microbiome-metabolome signature (bile acids and AI-2) in H. pylori patients. Abundance of certain bacteria that deconjugate bile acids along with increased AI-2 possibly gives selective advantage for H. pylori growth, further reducing microbial diversity. Taurine-conjugated bile acids inhibit H. pylori growth. We propose a model describing interplay of these factors in H. pylori disease progression, suggesting therapeutic targets worth exploring with rising antibiotic resistance.